Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardí
暂无分享,去创建一个
G. Lip | G. Boriani | T. Potpara | B. Williams | A. Oto | G. de Simone | A. Manolis | T. Kahan | M. Olsen | F. Marín | W. Tzou | A. Coca | J. Steffel | Wendy S. Tzou | M. J. de Oliveira Figueiredo | Chern En Chiang
[1] G. Lip. Stroke prevention in Atrial Fibrillation. , 2017, European heart journal.
[2] A. Camm,et al. Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[3] U. Schotten,et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation , 2017, European heart journal.
[4] F. Cosío,et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[5] G. Lip,et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[6] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[7] D. Lane,et al. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores , 2016, Journal of thrombosis and haemostasis : JTH.
[8] Hans Eiskjær,et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.
[9] M. Rienstra,et al. Rate control in atrial fibrillation , 2016, The Lancet.
[10] L. Fauchier,et al. Rhythm control in atrial fibrillation , 2016, The Lancet.
[11] L. Fauchier,et al. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? , 2016, Stroke.
[12] Hugh Calkins,et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2016, Heart rhythm.
[13] S. Anderson,et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.
[14] C. O’Seaghdha,et al. Single Agent Antihypertensive Therapy and Orthostatic Blood Pressure Behaviour in Older Adults Using Beat-to-Beat Measurements: The Irish Longitudinal Study on Ageing , 2016, PloS one.
[15] G. Lip,et al. Non-Vitamin K Antagonist Oral Anticoagulants , 2014, Springer International Publishing.
[16] F. Veglio,et al. Cardiac Organ Damage and Arterial Stiffness in Autonomic Failure: Comparison With Essential Hypertension. , 2015, HYPERTENSION.
[17] R. de Caterina,et al. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2015, Journal of the American Heart Association.
[18] G. de Simone,et al. Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network. , 2015, International journal of cardiology.
[19] R. Mahajan,et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. , 2015, Journal of the American College of Cardiology.
[20] G. Lip,et al. Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation , 2015, Stroke.
[21] Fabrizio Ricci,et al. Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. , 2015, Journal of the American College of Cardiology.
[22] G. Lip,et al. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score , 2015, Thrombosis and Haemostasis.
[23] O. Nielsen,et al. Excessive Atrial Ectopy and Short Atrial Runs Increase the Risk of Stroke Beyond Incident Atrial Fibrillation. , 2015, Journal of the American College of Cardiology.
[24] Y. Aizawa,et al. Cardiac innervation and sudden cardiac death. , 2015, Circulation research.
[25] J. Halperin,et al. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. , 2015, Journal of the American College of Cardiology.
[26] D. Capodanno,et al. Ventricular arrhythmias in aortic valve stenosis before and after transcatheter aortic valve implantation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[27] Frank Bogun,et al. Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy. , 2015, Heart rhythm.
[28] Michael Böhm,et al. Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. , 2015, The American journal of medicine.
[29] A. Oto,et al. A Prospective DE‐MRI Study Evaluating the Role of TGF‐β1 in Left Atrial Fibrosis and Implications for Outcomes of Cryoballoon‐Based Catheter Ablation: New Insights into Primary Fibrotic Atriocardiomyopathy , 2015, Journal of cardiovascular electrophysiology.
[30] T. Chao,et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? , 2015, Journal of the American College of Cardiology.
[31] 陈涵. ACC/AHA/HRS 发布新版成人室上性心动过速指南 , 2015 .
[32] T. Grodzicki,et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. , 2014, The American journal of cardiology.
[33] T. Potpara,et al. Diving to the foot of an iceberg: The SEARCH for undiagnosed atrial fibrillation , 2014, Thrombosis and Haemostasis.
[34] D. Singer,et al. Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry , 2014, Circulation.
[35] S. Tobe,et al. Combining other antihypertensive drugs with β-blockers in hypertension: a focus on safety and tolerability. , 2014, The Canadian journal of cardiology.
[36] Glenn Salkeld,et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies , 2014, Thrombosis and Haemostasis.
[37] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[38] P. Kirchhof,et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[39] G. Lip,et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation , 2014, European heart journal.
[40] I. Durand-zaleski,et al. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[41] Mukul Sharma,et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation , 2013, Thrombosis and Haemostasis.
[42] P. Lantelme,et al. Significance, prognostic value and management of heart rate in hypertension. , 2014, Archives of cardiovascular diseases.
[43] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[44] G. Lip,et al. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. , 2013, International journal of cardiology.
[45] G. Lip,et al. Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants , 2013, PharmacoEconomics.
[46] Alanna M. Chamberlain,et al. Temporal Relationship and Prognostic Significance of Atrial Fibrillation in Heart Failure Patients With Preserved Ejection Fraction: A Community-Based Study , 2013, Circulation.
[47] Jeroen J. Bax,et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.
[48] P. Kirchhof,et al. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. , 2013, European heart journal.
[49] G. Lip,et al. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry , 2013, PloS one.
[50] A. Uy‐Evanado,et al. Electrocardiographic Predictors of Sudden Cardiac Death in Patients with Left Ventricular Hypertrophy , 2013, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.
[51] E. Lo,et al. Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies , 2013, The Lancet Neurology.
[52] David D. McManus,et al. Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF Consortium , 2013, Journal of the American Heart Association.
[53] Prashanthan Sanders,et al. Long‐term Outcomes of Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta‐analysis , 2013, Journal of the American Heart Association.
[54] I. V. Van Gelder,et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. , 2013, JACC. Heart failure.
[55] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[56] Kazuomi Kario,et al. Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension. , 2012, American journal of hypertension.
[57] J. Halperin,et al. Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.
[58] G. Lip,et al. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. , 2012, Chest.
[59] Kyle W. Klarich,et al. Advances in Arrhythmia and Electrophysiology Premature Ventricular Contraction-Induced Cardiomyopathy A Treatable Condition , 2012 .
[60] K. Liestøl,et al. Upper Normal Blood Pressures Predict Incident Atrial Fibrillation in Healthy Middle-Aged Men: A 35-Year Follow-Up Study , 2012, Hypertension.
[61] Duanping Liao,et al. Premature Cardiac Contractions and Risk of Incident Ischemic Stroke , 2009, Journal of the American Heart Association.
[62] P. Benfield,et al. Esmolol , 2012, Drugs.
[63] J. Tolstrup,et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study , 2011, Thrombosis and Haemostasis.
[64] Hidayet Kayançiçek,et al. Assessment of atrial conduction time in patients with essential hypertension. , 2011, Journal of electrocardiology.
[65] D. Singer,et al. Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation , 2011, Circulation. Cardiovascular quality and outcomes.
[66] Donald R. Lynch. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[67] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.
[68] O. Osadchii. Mechanisms of hypokalemia‐induced ventricular arrhythmogenicity , 2010, Fundamental & clinical pharmacology.
[69] V. Pyrgakis,et al. Evaluation of left ventricular hypertrophy in patients requiring permanent pacing , 2010, Therapeutic advances in cardiovascular disease.
[70] K. Nagata,et al. Blood Pressure Levels and Bleeding Events During Antithrombotic Therapy: The Bleeding With Antithrombotic Therapy (BAT) Study , 2010, Stroke.
[71] L. Køber,et al. Excessive Supraventricular Ectopic Activity and Increased Risk of Atrial Fibrillation and Stroke , 2010, Circulation.
[72] M. Wright,et al. Controversies in cardiovascular medicine Drugs vs . ablation for the treatment of atrial fibrillation : the evidence supporting catheter ablation , 2010 .
[73] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[74] H. Calkins,et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. , 2010, The American journal of cardiology.
[75] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[76] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[77] L. Thijs,et al. Regression of Left Ventricular Mass by Antihypertensive Treatment: A Meta-Analysis of Randomized Comparative Studies , 2009, Hypertension.
[78] N J Wald,et al. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.
[79] A. Goette,et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles , 2009, European heart journal.
[80] Claudia Stöllberger,et al. Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.
[81] H. Crijns,et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. , 2008, JAMA.
[82] T. Young,et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Coun , 2008, Journal of the American College of Cardiology.
[83] M. Nieminen,et al. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study , 2008, Journal of hypertension.
[84] Marmar Vaseghi,et al. The role of the autonomic nervous system in sudden cardiac death. , 2008, Progress in cardiovascular diseases.
[85] H. Tse,et al. Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications , 2008, Journal of Human Hypertension.
[86] T. Ogihara,et al. Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial , 2008, Hypertension.
[87] Gregory Y H Lip,et al. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data , 2008, Thrombosis and Haemostasis.
[88] C. Pepine,et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). , 2007, European heart journal.
[89] N. Tribulova,et al. Adaptation of the heart to hypertension is associated with maladaptive gap junction connexin-43 remodeling. , 2008, Physiological research.
[90] G. Lip,et al. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. , 2007, QJM : monthly journal of the Association of Physicians.
[91] M. Nieminen,et al. Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy and Reduction in Sudden Cardiac Death: The LIFE Study , 2007, Circulation.
[92] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[93] S. Willich,et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[94] G. Lip,et al. Effect of hypertension on anticoagulated patients with atrial fibrillation. , 2007, European heart journal.
[95] Po Box,et al. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives:Data of the RACE study , 2007 .
[96] R. Tieleman,et al. Atrial extrasystoles after exercise predict atrial fibrillation in patients with left ventricular hypertrophy , 2005, Heart.
[97] T. Kahan,et al. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential , 2005, Heart.
[98] Silvia G Priori,et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Co , 2003, Circulation.
[99] W. DuMouchel,et al. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post‐marketing setting , 2003, Pharmacoepidemiology and drug safety.
[100] K. Borch-Johnsen,et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study , 2003, The Lancet.
[101] W. Elliott,et al. The Economic Impact of Hypertension , 2003, Journal of clinical hypertension.
[102] S. Mochizuki,et al. Hypertension‐Related Intermyocyte Junction Remodelling is Associated with a Higher Incidence of Low‐K+‐Induced Lethal Arrhythmias in Isolated Rat Heart , 2002, Experimental physiology.
[103] P Lavie,et al. Obstructive Sleep Apnea and Hypertension: From Correlative to Causative Relationship , 2001, Journal of clinical hypertension.
[104] M. Barbagallo,et al. Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. , 2001, American journal of hypertension.
[105] A. Oksenberg,et al. Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? , 2001, Current hypertension reports.
[106] K. Umetani,et al. Cardiac arrhythmias and left ventricular hypertrophy in dipper and nondipper patients with essential hypertension. , 2000, Japanese circulation journal.
[107] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[108] A. Saadeh,et al. QTc dispersion and complex ventricular arrhythmias in untreated newly presenting hypertensive patients , 1999, Journal of Human Hypertension.
[109] D. Levy,et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. , 1998, Journal of the American College of Cardiology.
[110] P A Wolf,et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.
[111] H. Gavras,et al. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. , 1998, American journal of hypertension.
[112] M. Barbagallo,et al. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. , 1997, American journal of hypertension.
[113] T. Raghunathan,et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. , 1994, The New England journal of medicine.
[114] D. Sideris. High blood pressure and ventricular arrhythmias. , 1993, European heart journal.
[115] M. Cheitlin,et al. Diuretics, Serum and Intracellular Electrolyte Levels, and Ventricular Arrhythmias in Hypertensive Men , 1992 .
[116] P. Macfarlane,et al. Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. , 1992, The American journal of cardiology.
[117] N. Kaplan. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. , 1988, The New England journal of medicine.
[118] D. Levy,et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. , 1987, The American journal of cardiology.
[119] R. Kleiger,et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. , 1986, The New England journal of medicine.
[120] W. Kannel,et al. Sudden death: lessons from subsets in population studies. , 1985, Journal of the American College of Cardiology.
[121] E. Bixler,et al. SLEEP APNOEA IN A HYPERTENSIVE POPULATION , 1984, The Lancet.
[122] G. Lip,et al. Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAMe-TT 2 R 2 Score , 2022 .